专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09257125B2 Audio frame timing correction method and wireless device 有权
标题翻译：音频帧定时校正方法和无线设备
公开(公告)号：US09257125B2
公开(公告)日：2016-02-09
申请号：US13983132
申请日：2012-01-24
申请人： Shinji Yokoyama
发明人： Shinji Yokoyama
IPC分类号： G10L19/00 , H04J3/06 , H04W52/02
CPC分类号： G10L19/0017 , G10L19/00 , H04J3/0632 , H04J3/0685 , H04W52/029 , Y02D70/00
摘要： An audio frame timing correction method and a wireless device are provided. A controller generates a reference clock for audio coding/decoding such that the reference clock runs fast and moved forward within an audio data sampling interval with the remaining time becoming a margin of the interval. An audio codec decodes demodulated data based on the reference clock, and codes an audio signal based on the reference clock. A demodulator detects wireless frame deviation and determines an adjustment timing whereat the wireless frame symbol timing and the audio frame timing are corrected based on the deviation and the margin. Upon the adjustment timing, the controller synchronizes audio sampling timing with the wireless frame symbol timing.
摘要翻译：提供了音频帧定时校正方法和无线设备。控制器生成用于音频编码/解码的参考时钟，使得参考时钟在音频数据采样间隔内快速运行并向前移动，其余时间成为间隔的余量。音频编解码器基于参考时钟解码解调数据，并且基于参考时钟对音频信号进行编码。解调器检测无线帧偏差，并且基于偏差和余量确定校正无线帧符号定时和音频帧定时的调整定时。在调整定时时，控制器将音频采样定时与无线帧符号定时同步。

2. 发明申请

US20100056613A1 SPIROQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION 失效
标题翻译：螺旋体化合物和药物组合物
公开(公告)号：US20100056613A1
公开(公告)日：2010-03-04
申请号：US12312640
申请日：2007-11-21
申请人： Shinji Yokoyama , Hashime Kanazawa , Tomoji Aotsuka
发明人： Shinji Yokoyama , Hashime Kanazawa , Tomoji Aotsuka
IPC分类号： A61K31/385 , C07D339/06 , A61P9/12 , A61P25/00 , A61P3/10 , A61P3/04 , A61P13/12 , A61P29/00
CPC分类号： C07D339/06
摘要： A novel spiroquinone derivative having a high ABCA1 stabilization effect and being useful for prophylactic and/or therapeutic agents for various diseases developing hypo-high density lipoproteinemia is obtained. The novel spiroquinone derivative is a compound represented by the following formula: wherein R1a, R1b, R1c and R1d each represents a hydrogen atom, a halogen atom, an alkyl group which may have a substituent, or an alkoxy group which may have a substituent, and R2a and R2b each represents a hydrogen atom, or an alkyl group which may have a substituent (e.g., a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, and an N-substituted carbamoyl group), the groups R2a and R2b may bond together to form a hydrocarbon ring with an adjacent carbon atom, provided that compounds in which all of the groups R1a, R1b, R1c and R1d are t-butyl groups, and both of the groups R2a and R2b are hydrogen atoms or both of the groups R2a and R2b are methyl groups are excluded; or a pharmacologically acceptable salt thereof.
摘要翻译：获得具有高ABCA1稳定作用并可用于发生低密度脂蛋白血症的各种疾病的预防和/或治疗剂的新型螺醌衍生物。新型螺醌衍生物为下式表示的化合物：其中R1a，R1b，R1c和R1d各自表示氢原子，卤素原子，可具有取代基的烷基或可具有取代基的烷氧基， R2a和R2b各自表示氢原子或可具有取代基的烷基（例如羧基，烷氧基羰基，氨基甲酰基和N-取代氨基甲酰基），基团R 2a和R 2b可以键合一起形成具有相邻碳原子的烃环，条件是其中所有基团R 1a，R 1b，R 1c和R 1d都是叔丁基，并且基团R 2a和R 2b各自为氢原子或两个基团 R2a和R2b是甲基; 或其药理学上可接受的盐。

3. 发明授权

US6046201A Pyridinecarboxamide derivatives 失效
标题翻译：吡啶甲酰胺衍生物
公开(公告)号：US6046201A
公开(公告)日：2000-04-04
申请号：US101441
申请日：1998-07-15
申请人： Norio Oshida , Yoji Mimaki , Hiroaki Satoh , Shinji Yokoyama , Yukiko Muraki , Kazumi Nishimura , Tamiko Hamada , Einosuke Sakurai , Hiroshi Sakai , Toshiji Sugai , Tomomi Tonoike , Koichi Itoh
发明人： Norio Oshida , Yoji Mimaki , Hiroaki Satoh , Shinji Yokoyama , Yukiko Muraki , Kazumi Nishimura , Tamiko Hamada , Einosuke Sakurai , Hiroshi Sakai , Toshiji Sugai , Tomomi Tonoike , Koichi Itoh
IPC分类号： C07D213/80 , C07D213/82 , A61K31/495 , C07D401/04
CPC分类号： C07D213/80 , C07D213/82
摘要： N-(12-Nitroxydodecyl)-6-(4-ethyl or isopropyl-1-piperazinyl)pyridine-3-carboxamide or physiologically acceptable salts thereof. The said compounds have excellent inhibiting activity of cerebral edema, especially ischemic cerebral edema, and inhibiting activity of delayed neuronal death (an inhibiting activity of Ca-influx in neuronal cells). Cerebral edema is a pathologic condition accompanying cerebrovascular disorders, especially the acute stage cerebrovascular disorders and then the compounds are useful as an inhibiting agent for cerebral edema or a therapeutic agent for cerebrovascular disorders. Moreover, because the compounds do hardly show a behavior suppressing action, which is considered to be side effect in treating cerebrovascular disorders at the acute stage, they are an excellent therapeutic agent for, in particular, the acute stage cerebrovascular disorders. Moreover, the compounds show a cerebral protective activity (an anti-anoxic activity), an activity of increasing cerebral blood flow, and an activity of inhibiting lipid peroxidation, and these activities may lead to the increased utility as a therapeutic agent for cerebrovascular disorders.
摘要翻译： PCT No.PCT / JP97 / 04208 Sec。 371日期：1998年7月15日 102（e）日期1998年7月15日PCT 1997年11月19日PCT PCT。出版物WO98 / 22440 日期1998年5月28日N-（12-硝基十二烷基）-6-（4-乙基或异丙基-1-哌嗪基）吡啶-3-甲酰胺或其生理上可接受的盐。所述化合物具有优异的脑水肿抑制活性，特别是缺血性脑水肿，抑制延迟性神经元死亡的活性（神经细胞内Ca流入的抑制活性）。脑水肿是伴随脑血管障碍，特别是急性期脑血管障碍的病理状况，然后该化合物可用作脑水肿的抑制剂或脑血管障碍的治疗剂。此外，由于化合物几乎不表现出在急性期治疗脑血管障碍中被认为是副作用的行为抑制作用，所以它们是特别是急性期脑血管障碍的优良治疗剂。此外，化合物显示脑保护活性（抗缺氧活性），增加脑血流量的活性和抑制脂质过氧化的活性，并且这些活性可导致作为脑血管障碍治疗剂的效用增加。

4. 发明授权

US5972943A Pyridinecarboxamide derivatives 失效
标题翻译：吡啶甲酰胺衍生物
公开(公告)号：US5972943A
公开(公告)日：1999-10-26
申请号：US101760
申请日：1998-07-20
申请人： Norio Oshida , Yoji Mimaki , Hiroaki Satoh , Shinji Yokoyama , Yukiko Muraki , Kazumi Nishimura , Tamiko Hamada , Einosuke Sakurai , Hiroshi Sakai , Toshiji Sugai , Tomomi Tonoike , Koichi Itoh
发明人： Norio Oshida , Yoji Mimaki , Hiroaki Satoh , Shinji Yokoyama , Yukiko Muraki , Kazumi Nishimura , Tamiko Hamada , Einosuke Sakurai , Hiroshi Sakai , Toshiji Sugai , Tomomi Tonoike , Koichi Itoh
IPC分类号： C07D213/80 , C07D213/82 , A61K31/495 , C07D401/04
CPC分类号： C07D213/80 , C07D213/82
摘要： Pyridinecarboxamide derivatives of the formula ##STR1## (wherein n represents an integer of 14-18, and R represents a hydrogen atom or a straight or branched C.sub.1 -C.sub.4 alkyl group) or physiologically acceptable salts thereof. The compounds have excellent inhibiting activity of cerebral edema, especially ischemic cerebral edema, and inhibiting activity of delayed death of neuronal cells (an inhibiting activity of Ca-influx in neuronal cells). Cerebral edema is a pathologic condition accompanying cerebrovascular disorders, especially the acute stage of cerebrovascular disorders and then the compounds are useful as an agent for inhibiting cerebral edema or a therapeutic agent for cerebrovascular disorders. Moreover, the compounds have no hypotensive action which is considered to be side-effect in treating the acute stage cerebrovascular disorders and hardly show a behavior suppressing action so that they are an excellent therapeutic agent for, in particular, the acute stage cerebrovascular disorders. Moreover, the compounds show a cerebral protective activity (an anti-anoxic activity), an increasing activity of cerebral blood flow, and an inhibiting activity of lipid peroxidation and these activities may lead to the increased utility as a therapeutic agent for cerebrovascular disorders.
摘要翻译： PCT No.PCT / JP97 / 04207 Sec。 371日期：1998年7月20日 102（e）1998年7月20日PCT PCT 1997年11月19日PCT公布。出版物WO98 / 22439 日期：1998年5月28日下式的吡啶甲酰胺衍生物（其中n表示14-18的整数，R表示氢原子或直链或支链的C 1 -C 4烷基）或其生理学上可接受的盐。该化合物具有优异的脑水肿抑制活性，特别是缺血性脑水肿，抑制神经元细胞延迟死亡的活性（神经细胞内Ca流入的抑制活性）。脑水肿是伴随脑血管障碍，特别是脑血管障碍的急性期的病理状况，然后该化合物可用作抑制脑水肿的药剂或脑血管障碍治疗剂。此外，化合物没有降压作用，被认为在治疗急性期脑血管障碍中具有副作用，并且几乎不显示行为抑制作用，因此它们是特别是急性期脑血管障碍的优良治疗剂。此外，化合物显示脑保护活性（抗缺氧活性），脑血流量的增加的活性和脂质过氧化的抑制活性，并且这些活性可能导致作为脑血管障碍治疗剂的效用增加。

5. 发明申请

US20100294002A1 OPTICAL FIBER PREFORM MANUFACTURING METHOD 审中-公开
标题翻译：光纤预制件制造方法
公开(公告)号：US20100294002A1
公开(公告)日：2010-11-25
申请号：US12780347
申请日：2010-05-14
申请人： Masahide ITO , Jun TERADA , Shinji YOKOYAMA , Mitsuhiro KAWASAKI
发明人： Masahide ITO , Jun TERADA , Shinji YOKOYAMA , Mitsuhiro KAWASAKI
IPC分类号： C03B37/01
CPC分类号： C03B37/01446
摘要： The present invention provides a method for manufacturing an optical fiber preform, which provides an optical fiber with stable transmission loss characteristics, and improves manufacturing efficiency. The method for manufacturing an optical fiber preform comprises dehydrating the optical fiber soot preform by lowering the optical fiber soot preform within the muffle tube and passing through a heating region, pulling up the dehydrated optical fiber soot preform to the predetermined position, and sintering the optical fiber soot preform by lowering the optical fiber soot preform again within the muffle tube and passing through the heating region where temperature of the heating region is higher than temperature of the heating region in dehydrating; wherein A≦B is satisfied where A is pull-up speed (mm/minute) of the optical fiber soot preform during the pulling up and B is gas flow rate (mm/minute) within the muffle tube at room temperature during the pulling up. Furthermore, 1.5×A≦B is satisfied.
摘要翻译：本发明提供一种光纤预制棒的制造方法，其提供具有稳定的传输损耗特性的光纤，并提高制造效率。制造光纤预制棒的方法包括：通过将马弗管内的光纤烟灰预制件下降并通过加热区域，将脱水的光纤烟灰预制件拉出到预定位置，并将光学玻璃烧结通过在马弗管内再次降低光纤烟灰预制件并通过加热区域的温度高于脱水加热区域的温度的加热区域，其中A＆NlE; B满足拉伸时光纤烟灰预成型件的上拉速度（mm /分钟），B为升温期间室温下马弗管内的气体流量（mm /分钟）。此外，满足1.5×A＆nlE; B。

6. 发明授权

US5847123A Imide derivatives for inhibiting the production of interleukin-1.beta. and the production of tumor necrosis factor .alpha. 失效
标题翻译：用于抑制白细胞介素-1β生成和产生肿瘤坏死因子α的酰亚胺衍生物
公开(公告)号：US5847123A
公开(公告)日：1998-12-08
申请号：US886540
申请日：1997-07-01
申请人： Shinji Yokoyama , Noriyoshi Sueda , Hiroaki Yamada , Ryotaro Kojima , Koichi Katsuyama
发明人： Shinji Yokoyama , Noriyoshi Sueda , Hiroaki Yamada , Ryotaro Kojima , Koichi Katsuyama
IPC分类号： C07C233/91 , C07C233/92 , C07C235/88 , C07D207/26 , C07D207/263 , C07D207/28 , C07D213/40 , C07D213/75 , C07D223/10 , C07D233/38 , C07D263/26 , C07D307/52 , C07D317/66 , C07D333/38 , A61K31/16 , A61K31/635 , C07C233/00 , C07D207/00 , C07D213/00 , C07D263/00
CPC分类号： C07D207/27 , C07C233/91 , C07C233/92 , C07C235/88 , C07D207/28 , C07D213/40 , C07D213/75 , C07D223/10 , C07D233/38 , C07D263/26 , C07D307/52 , C07D317/66 , C07D333/38
摘要： Imide compounds having a propioloyl group or pharmaceutically acceptable salts thereof which exhibit potent activities to inhibit the production of Interleukin 1-.beta. and also the production of Tumor Necrosis Factor .alpha.. These imide compounds are useful as a prophylactic or therapeutic agent for inhibiting the production of Interleukin 1-.beta. and the production of Tumor Necrosis Factor .alpha., typically for such diseases as chronic rheumatism, sepsis, ulcerative colitis, Crohn's disease and many other related diseases in which Interleukin 1-.beta. and/or Tumor Necrosis Factor .alpha. would participate.
摘要翻译：具有丙酰基的酰亚胺化合物或其药学上可接受的盐，其显示出有效的活性以抑制白细胞介素1-β的产生以及产生肿瘤坏死因子α。这些酰亚胺化合物可用作抑制白细胞介素1β的产生和肿瘤坏死因子α的产生的预防或治疗剂，通常用于慢性风湿病，败血症，溃疡性结肠炎，克罗恩病和许多其它相关疾病白细胞介素1β和/或肿瘤坏死因子α参与。

7. 发明授权

US5087709A Process for the preparation of 1.alpha.,25-dihydroxyvitamin D.sub.2 and the 24-epimer thereof 失效
标题翻译：制备1（ALPHA），25-二羟基维生素D2及其24-EPIMER的方法
公开(公告)号：US5087709A
公开(公告)日：1992-02-11
申请号：US333547
申请日：1989-04-04
申请人： Masahiro Tsuji , Shinji Yokoyama , Yoji Tachibana
发明人： Masahiro Tsuji , Shinji Yokoyama , Yoji Tachibana
IPC分类号： C07C67/00 , C07C401/00 , C07J9/00 , C07J71/00 , C07J75/00
CPC分类号： C07J9/00 , C07C401/00 , C07J71/0042
摘要： (22E)-5,7,22-Ergostatriene-1.alpha.,3.beta.,25-triol and the 24-epimer thereof which are new intermediates for the synthesis of 1.alpha.,25-dihydroxyvitamin D.sub.2 and the 24-epimer thereof. A new process for the preparation of 1.alpha.,25-dihydroxyvitamin D.sub.2 and the 24-epimer thereof is also described which comprises irradiation of (22E)-5,7,22-ergostatriene-1.alpha.,3.beta.,25-triol or the 24-epimer thereof followed by isomerization.
摘要翻译：（22E）-5,7,22 -Ergost三烯-1α，3β，25-三醇及其24-差向异构体，它们是用于合成1α，25-二羟基维生素D2及其24-差向异构体的新中间体。还描述了制备1α，25-二羟基维生素D 2及其24-差向异构体的新方法，其包括（22E）-5,7,22-麦角三烯-1α，3β，25-三醇或 24-差向异构体，随后异构化。

8. 发明授权

US08119686B2 Spiroquinone compound and pharmaceutical composition 失效
标题翻译：螺醌化合物和药物组合物
公开(公告)号：US08119686B2
公开(公告)日：2012-02-21
申请号：US12312640
申请日：2007-11-21
申请人： Shinji Yokoyama , Hashime Kanazawa , Tomoji Aotsuka
发明人： Shinji Yokoyama , Hashime Kanazawa , Tomoji Aotsuka
IPC分类号： A61K31/385 , C07D339/02
CPC分类号： C07D339/06
摘要： A novel spiroquinone derivative having a high ABCA1 stabilization effect and being useful for prophylactic and/or therapeutic agents for various diseases developing hypo-high density lipoproteinemia is obtained. The novel spiroquinone derivative is a compound represented by the following formula: wherein R1a, R1b, R1c and R1d each represents a hydrogen atom, a halogen atom, an alkyl group which may have a substituent, or an alkoxy group which may have a substituent, and R2a and R2b each represents a hydrogen atom, or an alkyl group which may have a substituent (e.g., a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, and an N-substituted carbamoyl group), the groups R2a and R2b may bond together to form a hydrocarbon ring with an adjacent carbon atom, provided that compounds in which all of the groups R1a, R1b, R1c and R1d are t-butyl groups, and both of the groups R2a and R2b are hydrogen atoms or both of the groups R2a and R2b are methyl groups are excluded; or a pharmacologically acceptable salt thereof.
摘要翻译：获得具有高ABCA1稳定作用并可用于发生低密度脂蛋白血症的各种疾病的预防和/或治疗剂的新型螺醌衍生物。新型螺醌衍生物为下式表示的化合物：其中R1a，R1b，R1c和R1d各自表示氢原子，卤素原子，可具有取代基的烷基或可具有取代基的烷氧基， R2a和R2b各自表示氢原子或可具有取代基的烷基（例如羧基，烷氧基羰基，氨基甲酰基和N-取代氨基甲酰基），基团R 2a和R 2b可以键合一起形成具有相邻碳原子的烃环，条件是其中所有基团R 1a，R 1b，R 1c和R 1d都是叔丁基，并且基团R 2a和R 2b各自为氢原子或两个基团 R2a和R2b是甲基; 或其药理学上可接受的盐。

9. 发明申请

US20070269527A1 Therapeutic agents for low HDL-cholesterolemia 审中-公开
标题翻译：低HDL-胆固醇血症的治疗剂
公开(公告)号：US20070269527A1
公开(公告)日：2007-11-22
申请号：US11819674
申请日：2007-06-28
申请人： Shinji Yokoyama , Reijiro Arakawa
发明人： Shinji Yokoyama , Reijiro Arakawa
IPC分类号： A61K35/12
CPC分类号： A61K31/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/55 , A61K38/57
摘要： The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
摘要翻译：本发明提供低HDL-胆固醇血症药物，预防和/或治疗性抗动脉硬化药物以及预防和治疗低HDL-胆固醇血症，动脉硬化及其相关疾病或病症的方法，其重点在于改善 HDL，而不诉诸基因工程技术。此外，本发明提供一种低HDL-胆固醇血症的临床有效药剂和包含至少一种半胱氨酸蛋白酶抑制剂作为活性成分的预防和/或治疗性抗动脉硬化剂，从而增加表达的ABCA1的量和提高血液HDL 水平，不使用遗传工程技术。

10. 发明申请

US20070161702A1 Abca1 stabilizer 失效
标题翻译： Abca1稳定剂
公开(公告)号：US20070161702A1
公开(公告)日：2007-07-12
申请号：US10586338
申请日：2004-12-22
申请人： Shinji Yokoyama , Maki Tsujita , Reijiro Arakawa , Tomoji Aotsuka
发明人： Shinji Yokoyama , Maki Tsujita , Reijiro Arakawa , Tomoji Aotsuka
IPC分类号： A61K31/343 , A61K31/05
CPC分类号： A61K31/385 , A61K31/05 , A61K31/122 , Y10S514/824
摘要： To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.
摘要翻译：提供用于低HDL胆固醇血症的药学上有效的预防/预防药物，重点是HDL生成机制。本发明的ABCA1稳定剂含有选自普罗布考螺醌，普罗布考二苯醌和普罗布考双酚作为有效成分的双酚型化合物。 ABCA1稳定剂可以通过与常规方法完全不同的机制连续稳定地表达ABCA1，因此可用作低HDL胆固醇血症或动脉硬化的预防/预防药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式